Patents by Inventor Anthony Allison
Anthony Allison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11927364Abstract: An air handling unit (AHU) for a heating, ventilation, air conditioning, and refrigeration (HVACR) system includes a housing and a combustion heater disposed within the housing. The housing includes a combustion section with a first channel and a second channel. The combustion heater includes heat exchanger tubes and a tube support that supports heat exchanger tubes within the combustion section. The tube support slidably disposed in the first channel and the second channel. The combustion heater configured to be slidably removable from the AHU. An AHU for an HVACR system includes a housing with a fan section and a fan assembly disposed within the housing. The fan assembly including a pair of grooves slidably disposed on a pair of rails of the housing. The fan assembly configured to be both slidably removable from the AHU and liftably removable from the AHU.Type: GrantFiled: December 31, 2020Date of Patent: March 12, 2024Assignee: TRANE INTERNATIONAL INC.Inventors: Christopher Daniel, Jason William Parks, Gregory L. Meeuwsen, Nathan Wagers, Chasity Webb, Anthony Chiles, Gregory Edmund Beltran, Aaron Allison Stevens, Stephen Kowalski, Jason Harpst
-
Patent number: 7635680Abstract: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothrombinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage. In addition, the modified annexin prevents lipid loss from platelets during storage.Type: GrantFiled: April 12, 2007Date of Patent: December 22, 2009Assignee: Alavita Pharmaceuticals, Inc.Inventor: Anthony Allison
-
Patent number: 7635678Abstract: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage.Type: GrantFiled: September 14, 2006Date of Patent: December 22, 2009Assignee: Alavita Pharmaceuticals, Inc.Inventor: Anthony Allison
-
Patent number: 7635676Abstract: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage.Type: GrantFiled: November 3, 2005Date of Patent: December 22, 2009Assignee: Alavita Pharmaccuticals, Inc.Inventor: Anthony Allison
-
Publication number: 20090291086Abstract: Modified annexin proteins, including heterodimers and homodimer of various human annexins, are provided for treatment of cerebral thrombosis and global cerebral ischemia. Also provided are phosphatidylserine (PS) binding proteins for treatment of cerebral thrombosis and global cerebral ischemia. The modified annexins and/or PS binding proteins bind PS on cell surfaces, thereby preventing the attachment of leukocytes and platelets to endothelial cells during post-ischemic reperfusion. By maintaining endothelial cell and vascular wall integrity PS binding proteins and/or modified annexin proteins decrease cerebral hemorrhage. Modified annexins and other PS binding proteins also suppress the production of mediators of edema, the extension of cerebral damage during reperfusion and the risk of rethrombosis. Thus, modified annexin proteins and/or other PS binding proteins decrease brain damage following cerebral thrombosis and global cerebral ischemia.Type: ApplicationFiled: May 21, 2009Publication date: November 26, 2009Applicant: ALAVITA PHARMACEUTICALS, INC.Inventor: ANTHONY ALLISON
-
Patent number: 7407475Abstract: A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.Type: GrantFiled: April 20, 2005Date of Patent: August 5, 2008Assignee: Alavita Pharmaceuticals, Inc.Inventor: Anthony Allison
-
Publication number: 20080069823Abstract: Compositions for and methods of attenuating and/or preventing ischemia-reperfusion injury (IRI) are provided. One method comprises administering to a patient in need thereof an agent that binds phosphatidylserine (PS) located on cell surfaces, i.e., PS binding agent. Another method comprises administering to an organ transplant recipient a therapeutic composition comprising a PS binding agent. A method of preventing IRI to cells is also provided. The method comprises adding a PS-binding agent to a therapeutic composition used to treat the cells. Further provided is a method of protecting an organ or a tissue susceptible to IRI. The method comprises contacting the organ or tissue with a PS-binding agent. Such an agent may, for example, attenuate IRI in patients with stroke or myocardial infarction, or following surgical operations. PS-binding agents include modified annexin proteins, antibodies against PS molecules, and other anti-PS molecules.Type: ApplicationFiled: April 12, 2007Publication date: March 20, 2008Applicant: ALAVITA PHARMACEUTICALS, INC.Inventor: Anthony Allison
-
Publication number: 20070268268Abstract: A touchpad device for use with electronic apparatus is disclosed. The device has an active area that is sensitive to movement thereon and to generate electrical signals in response thereto for inputting into the electronic apparatus. The active area of the device defines a plurality of active portions, each of which is arranged to produce an electrical signal in response to at least one defined movement thereon. The device is provided with mounting means comprising a deformable portion for mounting on a substrate of variable size. It is envisaged that the substrate would be one or more fingers of a user, whereby the active portions may be activated by movement thereover of the user's thumb.Type: ApplicationFiled: August 2, 2005Publication date: November 22, 2007Inventor: Anthony Allison
-
Publication number: 20070207150Abstract: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage.Type: ApplicationFiled: December 19, 2006Publication date: September 6, 2007Applicant: Alavita Pharmaceuticals, Inc.Inventor: Anthony Allison
-
Publication number: 20070054855Abstract: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage.Type: ApplicationFiled: September 14, 2006Publication date: March 8, 2007Inventor: Anthony Allison
-
Publication number: 20070015705Abstract: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage. In addition, the modified annexin prevents lipid loss from platelets during storage.Type: ApplicationFiled: July 14, 2006Publication date: January 18, 2007Inventor: Anthony Allison
-
Publication number: 20060105952Abstract: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage.Type: ApplicationFiled: November 3, 2005Publication date: May 18, 2006Inventor: Anthony Allison
-
Patent number: 6982154Abstract: Sickle-cell diseases are treated with annexin proteins that are modified to increase their half-life in the circulation.Type: GrantFiled: August 1, 2003Date of Patent: January 3, 2006Assignee: Surromed, Inc.Inventor: Anthony Allison
-
Patent number: 6962903Abstract: A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.Type: GrantFiled: February 21, 2002Date of Patent: November 8, 2005Assignee: Alavita, Inc.Inventor: Anthony Allison
-
Publication number: 20050222030Abstract: A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.Type: ApplicationFiled: March 10, 2005Publication date: October 6, 2005Inventor: Anthony Allison
-
Publication number: 20050197295Abstract: A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.Type: ApplicationFiled: April 20, 2005Publication date: September 8, 2005Inventor: Anthony Allison
-
Publication number: 20040086515Abstract: Sickle-cell diseases are treated with annexin proteins that are modified to increase their half-life in the circulation.Type: ApplicationFiled: August 1, 2003Publication date: May 6, 2004Applicant: SurroMed, Inc.Inventor: Anthony Allison
-
Publication number: 20030228263Abstract: Methods and pharmaceutical compositions containing the organic germanium polymer propagermanium are used for treating bone disorders such as myeloma bone disease, multiple myeloma, Paget's disease, secondary bone cancers, and periodontitis.Type: ApplicationFiled: April 10, 2003Publication date: December 11, 2003Applicant: SurroMed, Inc.Inventor: Anthony Allison
-
Publication number: 20030166532Abstract: A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. It does not, however, affect platelet aggregation necessary for hemostasis. The modified annexin molecule can be a homodimer of annexin, an annexin molecule coupled to one or more polyethylene glycol chains, or an annexin molecule coupled to another protein. By increasing the molecular weight of annexin, the modified annexin is made to remain in circulation for sufficient time to provide a sustained therapeutic effect.Type: ApplicationFiled: February 21, 2002Publication date: September 4, 2003Applicant: SURROMED, INC.Inventor: Anthony Allison
-
Publication number: 20020197278Abstract: Modified toxins including botulinum toxin or tetanus toxin coupled to polyethylene glycol, pharmaceutical compositions of modified toxins, and methods for their use are provided. The methods include treating inappropriate muscle contraction, and treatments for cosmetic purposes.Type: ApplicationFiled: June 21, 2002Publication date: December 26, 2002Applicant: SURROMED, INC.Inventor: Anthony Allison